Research output per year
Research output per year
Personal profile
Research interests
Lisa has a background in pharmacy and conducted her doctoral research 'Health economics of direct oral anticoagulants in the Netherlands' at the department of Pharmacotherapy, -epidemiology, and -economics — University of Groningen. Her research focusses on health economic modelling for reimbursement and clinical decision-making purposes, with special interest in using real-world data to populate models and expertise in cardiorenal metabolic diseases. Currently, Lisa is involved in various research projects and technical appraisals for the National Institute for Health and Care Excellence in the UK. Expertise: pharmacoeconomics, health economics, burden of disease, budget impact, health technology assessment, cost-effectiveness.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Senior Consultant, Health-Ecore B.V.
1-May-2023 → …
Member of the External Assessment Group, National Institute for Health and Care Excellence
2022 → …
Fingerprint
Dive into the research topics where Lisa de Jong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
Khoirunnisa, S. M., Suryanegara, A., de Jong, L., Setiawan, D. & Postma, M., 15-Mar-2024, (E-pub ahead of print) In: PharmacoEconomics - open. 8, p. 511–524 14 p.Research output: Contribution to journal › Review article › peer-review
Open AccessFile1 Citation (Scopus)6 Downloads (Pure) -
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
Paulissen, J. H. J., Seddik, A. H., Dunton, K. J., Livings, C. J., van Hulst, M., Postma, M. J., de Jong, L. A. & Freriks, R. D., Aug-2024, In: European Journal of Health Economics. 25, p. 689–699 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile3 Citations (Scopus)22 Downloads (Pure) -
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?
Wolters, S., de Jong, L. A., Jansen, C., Jansman, F. G. A. & Postma, M. J., 2024, In: Expert Review of Pharmacoeconomics and Outcomes Research. 24, 2, p. 251-265 15 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)50 Downloads (Pure) -
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
Khoirunnisa, S. M., Suryanegara, F. D. A., Setiawan, D., Postma, M. J. & de Jong, L. A., May-2024, In: PLoS ONE. 19, 5, 16 p., e0304483.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile40 Downloads (Pure) -
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data
de Jong, L. A., Li, X., Emamipour, S., van der Werf, S., Postma, M. J., van Dijk, P. R. & Feenstra, T. L., Sept-2024, In: Pharmacoeconomics. 42, p. 929–953 25 p.Research output: Contribution to journal › Review article › peer-review
Open AccessFile15 Downloads (Pure)
Datasets
-
Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands
de Jong, L. A. (Contributor), van Schoonhoven, A. (Contributor), Hofstra, H. S. (Contributor), Postma, M. J. (Contributor) & van Hoek, B. (Contributor), Taylor & Francis Group, 9-Oct-2021
DOI: 10.6084/m9.figshare.16779043.v1
Dataset